IDT Australia Ltd
ASX:IDT
IDT Australia Ltd
ASX:IDT
Price:
0.091 AUD
-4.21%
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
The Relative Value of one
IDT
stock under the Base Case scenario is
0.174
AUD.
Compared to the current market price of 0.091 AUD,
IDT Australia Ltd
is
Undervalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IDT
Relative Value
Base Case
0.174
AUD
Undervaluation 48%
Valuation Multiples
Multiples Across Competitors
IDT Competitors Multiples
IDT Australia Ltd Competitors
IDT Australia Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
IDT Australia Ltd
ASX:IDT
|
32m AUD | 3.1 | -4.9 | -3.8 | -3.8 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
717.6B USD | 21 | 136.9 | 61.8 | 71 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.8 | 46.5 | 34 | 37.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.9B USD | 4.4 | 8.9 | 11.9 | 15.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
324.7B USD | 5.3 | 140.8 | 33.5 | 53.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.4B GBP | 5.2 | 39.7 | 140.8 | 225.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.7B CHF | 4.3 | 13.4 | 9.8 | 16.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
170.7B CHF | 2.9 | 14.8 | 8.5 | 10.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.4B USD | 2.7 | 73.8 | 11 | 16.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
